Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $169,100.74 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 5,501 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.74, for a total value of $169,100.74. Following the sale, the insider directly owned 48,945 shares of the company’s stock, valued at $1,504,569.30. The trade was a 10.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total value of $55,967.40.

Pharvaris Trading Up 1.3%

Shares of NASDAQ:PHVS opened at $29.86 on Friday. The business has a 50-day moving average price of $28.72 and a 200 day moving average price of $27.07. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -9.39 and a beta of -2.34. Pharvaris N.V. has a 12-month low of $15.51 and a 12-month high of $33.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities research analysts predict that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PHVS has been the subject of a number of recent analyst reports. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Citizens Jmp cut their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 13th. Wedbush lifted their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Wolfe Research began coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Finally, Royal Bank Of Canada dropped their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.18.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System grew its position in Pharvaris by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris in the 4th quarter valued at about $35,000. Public Employees Retirement System of Ohio boosted its stake in shares of Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after buying an additional 1,300 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.